Picture EBD Group Asia Bio Partnering Forum 2025 Singapore to 18 Jul 650x100px

Product › Details

BAY 3713372 (formerly PH020, Bayer / Puhe BioPharma)

	Status	2025-03-26 development p1 start
	Organisation	Suzhou Puhe BioPharma Co.,Ltd.
	Group	Puhe BioPharma (Group)
	Source	Bayer AG. (3/26/25). "Press Release: Bayer and Puhe BioPharma Enter into Global License Agreement for Clinical Phase I PRMT5 inhibitor [Not intended for U.S. and UK Media]". Berlin & Beijing.

Record changed: 2025-03-31

Picture EBD Group BIO-Europe 2025 Wien Vienna to 25 Jul 650x200px

More documents for cancer drug

[1] BioNTech SE. (6/2/25). "Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types". Mainz & Prince...
[2] Genmab A/S. (3/22/25). "Press Release: Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.". Copenhagen....
[3] Vivesto AB. (3/18/25). "Press Release: Vivesto Licenses Apealea to China’s Zhida Pharmaceutical". Solna....
[4] Araris Biotech AG. (3/17/25). "Press Release: Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech"....
[5] AstraZeneca plc. (3/17/25). "Press Release: AstraZeneca Enters License Agreement with Alteogen for Subcutaneous Formulations of Multiple Oncology Assets"....
[6] Valo Therapeutics Oy. (3/10/25). "Press Release: Valo Therapeutics Announces EUR 19m of Investment Funding and Expanded Clinical Trials". Helsinki, Naples & Perth....
[7] Sun Pharmaceutical Industries Ltd.. (3/10/25). "Press Release: Sun Pharma to Acquire Checkpoint Therapeutics". Mumbai & Waltham, MA....
[8] Callio Therapeutics. (3/3/25). "Press Release: Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept". Seattle, WA & Singapore....
[9] Adcendo ApS. (2/26/25). "Press Release: Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02". Copenhagen....
[10] FibroGen, Inc.. (2/20/25). "Press Release: FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million". San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]